Rilmenidine

Rilmenidine, an innovative antihypertensive agent, is an orally active, selective I1 imidazoline receptor agonist. Rilmenidine is an alpha 2-adrenoceptor agonist. Rilmenidine induces autophagy. Rilmenidine acts both centrally by reducing sympathetic overactivity and in the kidney by inhibiting the Na+/H+ antiport. Rilmenidine modulates proliferation and stimulates the proapoptotic protein Bax thus inducing the perturbation of the mitochondrial pathway and apoptosis in human leukemic K562 cells[1][2][3].

Product Specifications

CAS Number

[54187-04-1]

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

Adrenergic Receptor; Apoptosis; Autophagy; Imidazoline Receptor

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; GPCR/G Protein; Neuronal Signaling

Applications

Cancer-programmed cell death

Field of Research

Cancer; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/rilmenidine.html

Purity

99.0

Solubility

10 mM in DMSO

Smiles

C1(NC(C2CC2)C3CC3)=NCCO1

Molecular Formula

C10H16N2O

Molecular Weight

180.25

Precautions

H315, H319, H320

References & Citations

[1]Reid JL. Rilmenidine: a clinical overview. Am J Hypertens. 2000;13 (6 Pt 2) :106S-111S.|[2]Srdic-Rajic T, et al. Rilmenidine suppresses proliferation and promotes apoptosis via the mitochondrial pathway in human leukemic K562 cells. Eur J Pharm Sci. 2016;81:172-180.|[3]Rose C, et al. Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease. Hum Mol Genet. 2010;19 (11) :2144-2153.